News about

OTR Therapeutics Raises USD 100 Million to Advance Transformative Therapies

OTR Therapeutics has secured USD 100 million in Series A funding to accelerate the development of its pipeline of differentiated therapies aimed at addressing major unmet needs across immunology, inflammation, oncology, and other disease areas.

| 05/12/2025 | By |  439

AstraZeneca Unveils Broadest Haematology Data Set Yet at ASH 2025

AstraZeneca is advancing its ambition to transform haematology care with new data from its expanding pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from 6–9 December 2025.

| 05/12/2025 | By |  514

Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations

Granules India Limited announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., successfully completed a GMP inspection by the U.S. Food and Drug Administration (FDA) with zero observations.

| 05/12/2025 | By |  265

Formycon, MS Pharma Ink MENA Deal for Keytruda Biosimilar FYB206

Formycon has signed an exclusive commercialisation agreement with MS Pharma for its Keytruda biosimilar candidate FYB206 in the MENA region. The deal includes an upfront payment, milestone-based fees, and a significant share of regional gross profits generated in the region.

| 05/12/2025 | By |  171

FDA Lifts Partial Clinical Hold on Vanda's Tradipitant for Motion Sickness

The lift allows Vanda to extend clinical studies of tradipitant in motion sickness. Meanwhile, the review of the fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track.

| 05/12/2025 | By |  450

Sanofi Completes Vicebio Takeover

This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.

| 05/12/2025 | By |  161

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

| 05/12/2025 | By |  181

Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US

Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.

| 05/12/2025 | By |  150

Aptar Acquires Sommaplast, Provider of Oral Dosing Pharma Packaging Solutions

The acquisition of Sommaplast strengthens Aptar’s pharmaceutical portfolio and expands its footprint in Latin America, giving the company access to Sommaplast’s established expertise in oral dosing components and its growing customer base across Brazil’s healthcare market.

| 04/12/2025 | By |  185

Continuous Tableting Breakthrough: GEA and Hovione Introduce ConsiGma CDC Flex System

GEA and Hovione have expanded their long-standing partnership with the launch of the ConsiGma CDC Flex system — a next-generation continuous direct compression (CDC) platform designed to deliver greater flexibility, simplicity and cost-efficiency in the development and production of oral solid dosage forms.

| 04/12/2025 | By |  243